The pharmacokinetics of injectable @entity208 in newborns with the XXXX .

@entity131 @entity3625 @entity63 @entity3624 @entity1699 @entity6652 @entity26 @entity1167 @entity208 @entity414
OBJECTIVE: The purpose of this investigation was to determine the pharmacokinetic disposition of intravenous @entity208 and its metabolite @entity6652 in neonates with the @entity1699 ( @entity1699 ) and to evaluate the subsequent degree of @entity3624 oxidase inhibition using serum @entity414 as a marker. METHODS: Pharmacokinetic data were evaluated in 12 stable preoperative neonates with @entity1699 after a single intravenous @entity208 administration of 5 mg/kg or 10 mg/kg. Pharmacokinetic parameters were determined for elimination half-life, clearance, volume of distribution, and mean residence time. @entity3624 oxidase inhibition, measured by serum @entity414 reduction, was also measured. RESULTS: Pharmacokinetic parameters revealed no statistically significant differences between a 5-mg/kg and 10-mg/kg dose of intravenous @entity208 on elimination half-life, clearance, volume of distribution, and mean residence time. Mean serum @entity414 levels were significantly reduced from baseline by 39.99 and 42.94%, respectively, in the 5- and 10-mg/kg treatment groups. DISCUSSION: The enzyme @entity3624 oxidase plays a key biochemical role in the generation of toxic @entity26 -derived free radicals during @entity63 -reperfusion conditions. @entity208 and its active metabolite @entity6652 inhibit @entity3624 oxidase, and significantly reduce the conversion of @entity3625 to @entity3624 and @entity3624 to @entity414 . @entity131 may be caused by toxic @entity26 free radicals produced by @entity63 -reperfusion injury such as could occur during the repair of @entity1699 under hypothermic total @entity1167 . We hypothesize that @entity208 may provide protection from cellular injury in this clinical context.
